Philip W. Kantoff, MD

Philip W. Kantoff, MD

Chief, Division of Solid Tumor Oncology
Director, Lank Center for Genitourinary Oncology
Chair, Executive Committee for Clinical Research

Professor of Medicine, Harvard Medical School

View Physician Profile

Video: Meet this Doctor 

Center/Program

Genitourinary Oncology

Department

Medical Oncology/Solid Tumor Oncology

Interests

Prostate cancer, Testicular cancer

Area of Research

Genitourinary Cancers: Genetics, Epidemiology, and Clinical Trials

Contact Information

Philip W. Kantoff, MD
Dana-Farber Cancer Institute
450 Brookline Avenue
Dana 1230
Boston, MA 02215
Office phone: 617-632-1914
Fax: 617-632-2165
E-mail: philip_kantoff@dfci.harvard.edu

Preferred contact method: office phone

Research

Genitourinary Cancers: Genetics, Epidemiology, and Clinical Trials

Our research team focuses on the molecular basis of genitourinary cancers and improved treatments for patients with prostate cancer, kidney cancer, bladder cancer, and testicular cancer. Laboratory research involves understanding the genetics of prostate cancer, while clinical research focuses on trials of novel therapeutics for genitourinary cancers.

In our laboratory, we have investigated germline and somatic genetic markers of prostate cancer phenotype, mechanisms of resistance to hormone therapy and the role of microRNAs in prostate cancer. Our clinical trials have focused on: - introducing chemotherapy or novel therapeutics to patients with high-risk localized prostate cancer - testing novel therapeutics in men with rising levels of prostate-specific antigen (PSA) following local therapy with agents such as rosiglitazone and celecoxib - testing novel theraputics in men with advanced prostate disease - treating renal cell carcinoma with antiVEGF-based therapies - Our work has led to the FDA approval of drugs for prostate cancer including chemotherapies mitoxatrone and cabazitaxel, to vaccines including Provenge. We have also played vital roles in the development of abiraterone and XL 184.

Biography

Dr. Kantoff graduated from Brown University Medical School in 1979. After completing his internship and residency in internal medicine at New York University Hospital and Bellevue Hospital, he spent four years at the National Institutes of Health conducting research in gene therapy. He joined DFCI in 1987 and became director of the Lank Center for Genitourinary Oncology in 1988. Dr. Kantoff is chief clinical research officer and chief of the Division of Solid Tumor Oncology at Dana-Farber. He is the leader of the Dana-Farber/Harvard Cancer Center Prostate Cancer Program, and director of the prostate cancer Specialized Program of Research Excellence (SPORE). He is Professor of Medicine at Harvard Medical School.

Select Publications

  • Eglitis MA, Kantoff PW, Gilboa E, Anderson WF. Gene expression in mice after high efficiency retroviral-mediated gene transfer. Science 1985;230:1395-8.
  • Kantoff PW, Kohn DB, Mitsuya H, Armentano D, Sieberg M, Zwiebel JA, Eglitis MA, McLachlin JR, Wiginton DA, Hutton JJ, Horowitz SD, Gilboa E, Blaese RM, Anderson WF. Correction of adenosine deaminase deficiency in human T and B cells using retroviral-mediated gene transfer. Proc Natl Acad Sci USA 1986;83:6563-7.
  • Kantoff PW, Gillio A, McLachlin JR, Bordignon C, Eglitis MA, Kernan N, Moen R, Kohn DB, Karson E, Karlsson S, Zwiebel JA, Gilboa E, Blaese RM, Nienhuis A, O'Reilly R, Anderson WF. Expression of human adenosine deaminase in non-human primates after retroviral mediated gene transfer. J Exp Med 1987;166:219-34.
  • Kantoff PW, Flake AW, Eglitis MA, Harrison MR, Gilboa E, Zanjani ED, Anderson WF. In utero gene transfer and expression: a sheep transplantation model. Blood 1989;73:1066-73.
  • Giovannucci E, Stampfer M, Krithivas K, Brown M, Brufsky A, TalcottJ, Hennekens C, Kantoff PW. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci 1997;94:3320-3323.
  • Ghossein R, Rosai J, Scher H, Seiden M, Krithivas K, Chang G, Berlane K, Kantoff PW. Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma. Urology 1997;50(1):100-105.
  • Talcott JA, Rieker P, Propert K, Clark J, Wishnow KI, Loughlin KR, Cunnion M, Richie J, Kantoff PW. Patient reported impotence and incontinence after nerve-sparing radical prostatectomy. JNCI 1997;89(15):1117-1123.
  • Talcott JA, Rieker P, Clark J, Propert K, Kalish L, Weeks J, Beard C, Wishnow KI, Kaplan I, Loughlin KR, Cram R, Richie J, Kantofff PW. Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. J Clin Onc 1998;16:275-283.
  • Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer E, Vogelzang N. Hydrocortisone (H) with or without mitoxantrone (M) in men with hormone refractory prostate cancer (HRPC). The results of CALGB 9182. J Clin Onc 1999;17(8):2506-13.
  • Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman D, Oh W, Demetri G, Figg W, Zhou X, Eng C, Spiegelman B, Kantoff PW. Effects of ligand activation of PPAR human prostate cancer. Proc Natl Acad Sci 2000;97:10,990-95.
  • D'Amico A, Schultz D, Loffredo M, Dugal R, Hurwitz M, Beard C, Kaplan I, Renshaw A, Kantoff PW. Biochemical outcome following radiation therapy with or without androgen suppression therapy with clinically localized prostate cancer. JAMA 2000 Sep. 13;284(10):1280-3.
  • Kantoff PW, Halabi S, Farber DA, Hayes DF, Vogelzang NA, Small EJ. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate specific antigen in men with androgen independent prostate cancer. J Clin Oncol 2001 Jun 15:19(12):2238-45.
  • Smith MR, McGovern FJ, Zietman A, Fallon MA, Hayden D, Schoenfeld D, Kantoff PW, Finkelstein J, Pamidronate to prevent bone loss in men receiving gonadotropin-releasing hormone agonist therapy for prostate cancer. N Engl J Med 2001 Sep 27;345(13):948-55.
  • Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, Kantoff PW. Changes in body composition in men receiving initial gonadotropin releasing hormone agonist treatment for nonmetastatic prostate cancer. JCEM 2002 Feb; 87(2):599-603.
  • Halabi S, Hayes D, Vogelzang N, Small E, Kantoff PW. The prognostic significance of reverse transcriptase polymerase chain reaction (RT-PCR) for prostate specific antigen (PSA) in prostate cancer patients with one prior hormonal therapy: a nested study within CALGB 9583. J Clin Oncol Feb 2003;21(3):490-495.
  • Majumder PK, Yeh JJ, George DJ, Febbo PG, Kum J, Que X, Bikoff R, Ma H, Kantoff PW, Golub TR, Loda M, Sellers WR. Prostate intraepithelial neoplasia induced by prostate restricted akt activation the MPAKT model. Proc Natl Acad Sci, June 2003: 100(13):7841-7846.
  • George D, Halabi S, Shepard TF, Sanford B, Vogelzang NJ, Small EJ, Kantoff PW. The prognostic significance of plasma interleukin-6 (IL-6) levels in patients with metastatic hormone-refractory prostate cancer (HRCaP): Results from CALGB 9480. Clin Cancer Res 2005 MAr 1;11(5):1815-20.
  • Taplin ME, George DJ, Halabi S, Sanford B, Febbo PG, Hennessy KT, Mihos CG, Vogelzang NJ, Small EJ, Kantoff PW. The prognostic significance of plasma chromogranin A levels in hormone-refractory prostate cancer patients treated on Cancer and Leukemia Group B (CALGB) 9480. Urology 2005 Aug;66(2):386-91.
  • Li Hi, Kantoff PW, Giovannucci E, Leitzmann M, Gaziano JM, Stampfer MJ, Ma J. Manganese superoxide dismutase (MnSOD) polymorphism, prediagnostic plasma antioxidants and prostate cancer risk. Cancer Res 2005 Mar 15;65(6):2498-504.
  • Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D, Mehra R, Montie JE, Pienta KJ, Sanda MG, Kantoff PW, Rubin MA, Wei JT, Ghosh D, Chinnaiyan AM. Autoantibody signatures in prostate cancer. N Engl J Med 2005 Sep 22;353(12):1224-35.
  • Ross RW, Manola J, Hennesey K, Galsky M, Scher H, Small E, Kelly WK, Kantoff PW. Prognostic significance of baseline reverese transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy. Clin Cancer Res 2005 Jul 15;11(14):5195-8.
  • Farokhzad OC, Cheng J, Teply B, Sherifi I, Jon S, Kantoff PW, Richie JP, Langer R. Targeted nanoparticle-aptamer bioconjugates result in total tumor reduction in vivo. Proc Natl Acad Sci USA. 2006 Apr 18;103(16):6315-20.
  • Smith MR, Manola J, Kaufman DS, Oh WK, Bubley JG, Kantoff PW. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol. 2006 Jun 20;24(18):2723-8.
  • Humphrey PA, Halabi S, Picus J, Sanford B, Vogelzang NJ, Small EJ, Kantoff PW. Prognostic significance of plasma scatter factor hepatocyte growth factor levels in patients with metastatic hormone refractory prostate cancer: results from cancer and Leukemia Group B 150005/9480. Clin Genitourin Cancer. 2006 Mar;4(4):269-74.
  • Oh WK, Hayes J, Evan C, Manola J, George DJ, Waldron H, Donovan M, Varner J, Orechia J, Katcher B, Lu D, Nevins A, Wright RL, Tormey L, Talcott J, Rubin MA, Loda MA, Sellers WR, Richie JP, Kantoff PW#, Weeks J#. Development of an integrated prostate cancer research information system: Prostate CRIS. Clin Genitourin Cancer. 2006 Jun;5(1):61-6. #-equal contribution
  • D'Amico AV, Goldhaber SZ; Chen MH, Loffredo M, RN, Renshaw AA, Loffredo B; PW Kantoff, Hormonal Therapy for Prostate Cancer and the Time Courseto Cardiovascular Death. J. Clin Onc 2007 Jun 10;25(17):2420-5.
  • D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantof PW. Androgen Suppression and Radiation vs Radiation for Prostate Cancer: A Randomized Trial and Analysis of the Prognostic Significance of Comorbidity. JAMA. 2008 Jan 23;299(3):289-95.
  • Ross RW, Oh WK, Xie W, Pomerantz M, Nakabayashi M, Sartor O, Taplin ME, Regan MM, Kantoff PW*, freedman M*. Inherited variation in the androgen pathway is associated with the efficacy of androgen deprivation therapy in men with prostate cancer. J Clin Oncol. 2008 Feb 20;26(2):842-7. *-contributed equally.
  • D'Amico AV, Halabi S, Vollmer R, Loffredo M, McMahon E, Sanford B, Archer L, Vogelzang NJ, Small EJ, Kantoff PW. p53 Protein Expression Status and Recurrence in Men Treated with Radiation and Androgen Suppression Therapy for Higher-Risk Prostate Cancer: A Prospective Phase II Cancer and Leuikemia Group B Study (CALGB 9682). Urology. 2008 May;71(5):933-7.
  • Tomlins S, Rhodes D, Yu J; Varambally S; Mehra R, Perner S, Demichelis F, Helgeson B, Laxman B, Morris D, Cao Q, Cao X, Andren O, Fall K; Johnson L, Wei J, Shah R, Al-Ahmadie H, Eastham J, Eggener S, Fine S, Hotakainen K, Stenman U, Tsodikov A, Gerald W, Lilja H, Reuter V, Kantoff PW, Scardino P, Rubin M, Bjartell A, Chinnaiyan A. The Role of SPINK1 in ETS Rearrangement Negative Prostate Cancers. Cancer Cell. 2008 Jun;13(6):519-28.
  • D'Amico AV, Chen Mh, Renshaw AA, Loffredo B, Kantoff PW. Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy. J Clin Onc. 2008 Jun 20; 26(18):2979-83.
  • D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer. Cancer. 2008 DEc 15;113(12):3290-7.
  • Chan JM*, Oh WK*, Xie W, Regan MM, Stampfer MJ, King IB, Abe M, Kantoff PW. *Contributed equally. Plasma selenium, manganese superoxide dismutase (SOD2), and intermediate or high risk prostate cancer. J Clin Oncol. 2009 Jun 15. [Epub ahead of print]
  • Wang Q, Li W, Zhang Y, Yuan X, Beroukhim R, Wang H, Lupien M, Wu T, Regan MM, Meyer CA, Carroll JS, Manrai AK, Janne OA, Balk SP, Mehra R, Chinnaiyan A, Rubin MA, True L, Fiorentino M, Fiore C, Loda M, Kantoff PW, Liu XS and Brown M. Reprogrammed androgen receptor function in androgen independent prostate cancer. Cell 2009 Jul 23;128(2):245-56.
  • Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, and Godfrey WR. Overall survival (OS) analysis of a Phase II randomized controlled trial (RCT) of a poxviral-based PSA targeted immunotherapy in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2010 Jan 25. [Epub ahead of print].
  • Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, and Schellhammer PF for the IMPACT Study Investigators. Sipuleucel-T, Immunotherapy for Castration Resistant Prostate Cancer. N. Eng. J. Med 2010. 363:5: 1-12.
  • Sun T, Lee GM, Oh WK, Pomerantz M, Yang M, Xie W, Freedman ML, Kantoff PW. Single-nucleotide Polymorphisms in p53 Pathway and Aggressiveness of Prostate Cancer in a Caucasian Population Cancer Res. Clin Cancer REs. 2010 Nov 1;16(21):5244-51. Epub 2010 Sep 20.
  • Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, Kantoff PW, Stewart ST, Bhatnagar V, Sweeney CJ, Stahl JE. McMahon PM. Active Surveillance Compared With Initial Treatment for Men With Low-Risk Prostate Cancer: A Decision Analysis. JAMA. 2010 DEc1;304(21):2373-80.
  • Sun T, Oh WK, Lee GS, Pienta K, Kantoff PW. Inherited Variants in the Chemokine CCL2 Gene and Prostate Cancer Aggressiveness in a Caucasian Cohort. Clin  Cancer Res. (in press)
  • Berger MF, Lawrence MS, Demichelis F, Cibulskis K, Sivachenko A, Sboner A, Esgueva R, Pflueger D, Sougnez C, Onofrio R, Carter S, Drier Y, Ambrogio L, Fenne T, Parkin M, Gordon S, Voet D, Ramos A, Pugh T, Wilkinson J, Fisher S, Winckler W, Mahan S, Ardlie K, Baldwin J, Kitabayashi N, MacDonald TY, Kantoff PW, Gabriel SB, Gerstein MB, Golub TR, Meyerson M, Tewari A, Lander ES, Getz G, Rubin MA, Garraway LA. Characterization of complex chromosomal aberrations in primary prostate cancer genomes. Nature (in press)

Investigators

  • Elfiky, Aymen, MD
  • Rosenberg, Jonathan, MD
  • Freedman, Matthew, MD
  • Choueiri, Toni, MD
  • Hayes, Julia, MD
  • Pomerantz, Mark, MD

Trainees

  • Sun, Tong, PhD
  • Hsieh, Chen-Lin, PhD

Take The First Step
Make AN Appointment

Boston, Main Campus
877-332-4294

Online Appointments

South Shore
781-624-5000


MILFORD
877-332-4294

Patient Stories

Read inspiring stories of strength,
hope and perseverance.

© 2013; Dana-Farber/Brigham and Women's Cancer Center, Boston, MA